DCA and Avemar now shows promise against both AML and CLL Leukemia
PR Log - Jun 08, 2012 - Leukemia is known to be one of the most pernicious forms of cancer. Yet combining two mild, non-chemotherapy agents, dramatic clinical (in vivo) results have been achieved.
As a follow up to a previous report of DCA and Avemar working against AML Leukemia, a new case has surfaced of the protocol working against Chronic lymphocytic leukemia (CLL) Leukemia.
The term “chronic” in chronic lymphocytic leukemia comes from the fact that it typically progresses more slowly than other types of leukemia. The term “lymphocytic” in chronic lymphocytic leukemia comes from the cells affected by the disease — a group of white blood cells called lymphocytes, which help your body fight infection.